Diabetic retinopathy

J. Fernando Arévalo; Andres F. Lasave; David G. Zeballos; Sergio Bonafonte-Roy

doi:10.1007/978-1-4614-3646-1_21

Diabetic retinopathy

J. Fernando Arévalo, Andres F. Lasave, David G. Zeballos, Sergio Bonafonte-Roy

School of Medicine

Research output: Chapter in Book/Report/Conference proceeding › Chapter

1 Scopus citations

Abstract

Diabetic retinopathy remains a major threat to sight in the working-age population in the developed world. In proliferative diabetic retinopathy (PDR), the growth of new vessels is thought to occur as a result of vascular endothelial growth factor (VEGF) release into the vitreous cavity as a response to ischemia, which facilitates the process of angiogenesis and macular edema. In these patients, the introduction of new therapies, such as VEGF inhibitors, may have a beneficial effect on diabetic retinopathy including diabetic macular edema and retinal neovascularization, and these therapies could complement laser photocoagulation treatment.

Original language	English (US)
Title of host publication	Retinal and Choroidal Manifestations of Selected Systemic Diseases
Publisher	Springer New York
Pages	387-416
Number of pages	30
ISBN (Electronic)	9781461436461
ISBN (Print)	9781461436454
DOIs	https://doi.org/10.1007/978-1-4614-3646-1_21
State	Published - Jan 1 2013

Keywords

Diffuse diabetic macular edema
Nonproliferative diabetic retinopathy
Proliferative diabetic retinopathy
Retinal photocoagulation
Tractional retinal detachment
VEGF inhibitors
Vascular endothelial growth factor

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1007/978-1-4614-3646-1_21

Cite this

@inbook{bb41311d7ae14f2b93b053f7532fbd8b,

title = "Diabetic retinopathy",

abstract = "Diabetic retinopathy remains a major threat to sight in the working-age population in the developed world. In proliferative diabetic retinopathy (PDR), the growth of new vessels is thought to occur as a result of vascular endothelial growth factor (VEGF) release into the vitreous cavity as a response to ischemia, which facilitates the process of angiogenesis and macular edema. In these patients, the introduction of new therapies, such as VEGF inhibitors, may have a beneficial effect on diabetic retinopathy including diabetic macular edema and retinal neovascularization, and these therapies could complement laser photocoagulation treatment.",

keywords = "Diffuse diabetic macular edema, Nonproliferative diabetic retinopathy, Proliferative diabetic retinopathy, Retinal photocoagulation, Tractional retinal detachment, VEGF inhibitors, Vascular endothelial growth factor",

author = "Ar{\'e}valo, {J. Fernando} and Lasave, {Andres F.} and Zeballos, {David G.} and Sergio Bonafonte-Roy",

note = "Publisher Copyright: {\textcopyright} Springer Science+Business Media New York 2013.",

year = "2013",

month = jan,

day = "1",

doi = "10.1007/978-1-4614-3646-1_21",

language = "English (US)",

isbn = "9781461436454",

pages = "387--416",

booktitle = "Retinal and Choroidal Manifestations of Selected Systemic Diseases",

publisher = "Springer New York",

}

TY - CHAP

T1 - Diabetic retinopathy

AU - Arévalo, J. Fernando

AU - Lasave, Andres F.

AU - Zeballos, David G.

AU - Bonafonte-Roy, Sergio

N1 - Publisher Copyright: © Springer Science+Business Media New York 2013.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Diabetic retinopathy remains a major threat to sight in the working-age population in the developed world. In proliferative diabetic retinopathy (PDR), the growth of new vessels is thought to occur as a result of vascular endothelial growth factor (VEGF) release into the vitreous cavity as a response to ischemia, which facilitates the process of angiogenesis and macular edema. In these patients, the introduction of new therapies, such as VEGF inhibitors, may have a beneficial effect on diabetic retinopathy including diabetic macular edema and retinal neovascularization, and these therapies could complement laser photocoagulation treatment.

AB - Diabetic retinopathy remains a major threat to sight in the working-age population in the developed world. In proliferative diabetic retinopathy (PDR), the growth of new vessels is thought to occur as a result of vascular endothelial growth factor (VEGF) release into the vitreous cavity as a response to ischemia, which facilitates the process of angiogenesis and macular edema. In these patients, the introduction of new therapies, such as VEGF inhibitors, may have a beneficial effect on diabetic retinopathy including diabetic macular edema and retinal neovascularization, and these therapies could complement laser photocoagulation treatment.

KW - Diffuse diabetic macular edema

KW - Nonproliferative diabetic retinopathy

KW - Proliferative diabetic retinopathy

KW - Retinal photocoagulation

KW - Tractional retinal detachment

KW - VEGF inhibitors

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=84949008716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949008716&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-3646-1_21

DO - 10.1007/978-1-4614-3646-1_21

M3 - Chapter

AN - SCOPUS:84949008716

SN - 9781461436454

SP - 387

EP - 416

BT - Retinal and Choroidal Manifestations of Selected Systemic Diseases

PB - Springer New York

ER -

Diabetic retinopathy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this